๋„“์€ QRS ๋นˆ๋งฅ์—์„œ ํ”„๋กœ์นด์ธ์•„๋งˆ์ด๋“œ / Procainamide for wide-complex tachycardia

์ •์˜

Procainamide๋Š” stable wide-QRS VT ๋˜๋Š” ์ง€์†/์žฌ๋ฐœ VT์—์„œ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ๋Š” ํ•ญ๋ถ€์ •๋งฅ์ œ์ด๋‹ค. raw ์ž๋ฃŒ์—์„œ๋Š” amiodarone๊ณผ ํ•จ๊ป˜ ์•ฝ์ œ ์˜ต์…˜์œผ๋กœ ์ œ์‹œ๋˜์—ˆ๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

๋งฅ๋ฐ• ์žˆ๋Š” ๋ถˆ์•ˆ์ • regular monomorphic VT์˜ ์ฒซ ์ฒ˜์น˜๋Š” synchronized cardioversion์ด๋‹ค. refractory/recurrent ์ƒํ™ฉ์—์„œ๋Š” shock ์—๋„ˆ์ง€ ์ฆ๊ฐ€, ์›์ธ ๊ต์ •, ํ•ญ๋ถ€์ •๋งฅ์ œ, expert consultation์„ ํ•จ๊ป˜ ์ง„ํ–‰ํ•œ๋‹ค. procainamide๋Š” prolonged QT ๋˜๋Š” CHF๊ฐ€ ์žˆ์œผ๋ฉด ํ”ผํ•ด์•ผ ํ•œ๋‹ค.

์ง„๋‹จ

ํˆฌ์—ฌ ์ค‘ ์ €ํ˜ˆ์••, QRS widening, ๋ฆฌ๋“ฌ ๋ณ€ํ™” ์—ฌ๋ถ€๋ฅผ ๋ชจ๋‹ˆํ„ฐ๋งํ•œ๋‹ค. QT prolongation, ์‹ฌ๋ถ€์ „, ์ „ํ•ด์งˆ ์ด์ƒ, ACS ๋“ฑ ์•ฝ์ œ ์„ ํƒ์— ์˜ํ–ฅ์„ ์ฃผ๋Š” ์กฐ๊ฑด์„ ํ™•์ธํ•œ๋‹ค.

์น˜๋ฃŒ

์šฉ๋Ÿ‰: 20โ€“50 mg/min IV๋กœ ํˆฌ์—ฌํ•˜๋ฉฐ arrhythmia suppression, hypotension, QRS >50% widening, ๋˜๋Š” ์ตœ๋Œ€ 17 mg/kg์— ๋„๋‹ฌํ•˜๋ฉด ์ค‘๋‹จํ•œ๋‹ค. ์œ ์ง€ ์šฉ๋Ÿ‰์€ 1โ€“4 mg/min์ด๋‹ค. ๋™๊ธฐํ™” ๋ถˆ๊ฐ€, polymorphic VT, ๋ฌด๋งฅ์„ฑ ์ „ํ™˜ ์‹œ์—๋Š” procainamide๋ณด๋‹ค defibrillation ๋ฐ cardiac arrest ACLS ์ „ํ™˜์ด ์šฐ์„ ์ด๋‹ค.

์ถœ์ฒ˜

AHA 2025 Adult Tachyarrhythmia With a Pulse Algorithm.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.